Lees-Rolfe Garth has filed 8 insider transactions across 1 company since April 2024.
Most recent transaction: a disposition of 5834 shares of Inhibikase Therapeutics, Inc. ($IKT) on January 21, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 21, 2025 | Inhibikase Therapeutics, Inc. | $IKT | Lees-Rolfe Garth | Chief Financial Officer | D | Stock Option (Right to Buy) | 5834 | $0.00 | 0.0000 | 23,712,220 | 100.00% | 0.02% |
| Jan. 21, 2025 | Inhibikase Therapeutics, Inc. | $IKT | Lees-Rolfe Garth | Chief Financial Officer | A | Stock Option (Right to Buy) | 5834 | $0.00 | 5,834.0000 | 23,712,220 | 9999.99% | 0.02% |
| Jan. 21, 2025 | Inhibikase Therapeutics, Inc. | $IKT | Lees-Rolfe Garth | Chief Financial Officer | D | Stock Option (Right to Buy) | 90000 | $0.00 | 0.0000 | 23,712,220 | 100.00% | 0.38% |
| Jan. 21, 2025 | Inhibikase Therapeutics, Inc. | $IKT | Lees-Rolfe Garth | Chief Financial Officer | A | Stock Option (Right to Buy) | 90000 | $0.00 | 90,000.0000 | 23,712,220 | 9999.99% | 0.38% |
| Jan. 3, 2025 | Inhibikase Therapeutics, Inc. | $IKT | Lees-Rolfe Garth | Chief Financial Officer | A | Stock Option (Right to Buy) | 470861 | $0.00 | 470,861.0000 | 23,712,220 | 9999.99% | 1.99% |
| Jan. 3, 2025 | Inhibikase Therapeutics, Inc. | $IKT | Lees-Rolfe Garth | Chief Financial Officer | A | Stock Option (Right to Buy) | 235383 | $0.00 | 235,383.0000 | 23,712,220 | 9999.99% | 0.99% |
| Jan. 3, 2025 | Inhibikase Therapeutics, Inc. | $IKT | Lees-Rolfe Garth | Chief Financial Officer | A | Stock Option (Right to Buy) | 432853 | $0.00 | 432,853.0000 | 23,712,220 | 9999.99% | 1.83% |
| April 1, 2024 | Inhibikase Therapeutics, Inc. | $IKT | Lees-Rolfe Garth | Chief Financial Officer | A | Stock Option (right to buy) | 90000 | $0.00 | 90,000.0000 | 6,028,210 | 9999.99% | 1.49% |